AI-based Skeleton Recognition System for Rehabilitation Exercise in Breast Cancer Survivor
This study aims to develop and evaluate an artificial intelligence (AI)-based skeletal recognition system designed to support real-time, interactive rehabilitation exercise (RE programs. The goal is to mitigate musculoskeletal symptoms associated with endocrine therapy in breast cancer survivors.Endocrine therapy remai
| Condition(s) | Musculoskeletal Symptoms, Breast Cancer, Endocrine Therapy, Aromatase Inhibitors |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This study aims to develop and evaluate an artificial intelligence (AI)-based skeletal recognition system designed to support real-time, interactive rehabilitation exercise (RE programs. The goal is to mitigate musculoskeletal symptoms associated with endocrine therapy in breast cancer survivors.Endocrine therapy remains a cornerstone in the treatment of hormone receptor-positive breast cancer, typically extending over 5 to 10 years. While the therapeutic benefits of endocrine therapy are well established, agents such as aromatase inhibitors frequently induce musculoskeletal symptoms (MS), including joint pain, stiffness (particularly morning stiffness), carpal tunnel syndrome, tenosynovitis, myalgia, and muscle weakness. These symptoms, which may be continuous or intermittent, can affect |
| Who can participate | Inclusion Criteria: * 1\. Pathologically confirmed hormone receptor-positive breast cancer (stage I, II, III). 2\. Initiation of treatment with aromatase inhibitors (e.g., anastrozole, letrozole, exemestane). 3\. Postmenopausal women, including those with surgically induced menopause. 4. Clear consciousness, no cognitive or communication impairments, and able to comply with the intervention. 5\. Informed consent obtained, with voluntary participation in the study. 6. Bone and joint symptoms with a Brief Pain Inventory (BPI) score of ≥3, or presence of at least one of the following risk factors: elevated bone turnover markers, reduced vitamin D levels, increased inflammatory cytokines, elevated C-reactive protein, or elevated rheumatoid factor. 7\. Not participating in any physical therapy |
| Sex | All |
| Lead sponsor | Fudan University |
| Locations | Shanghai, China |
| Start date | 2024-10-20 |
| NCT ID | NCT06642948 |
| Official listing | https://clinicaltrials.gov/study/NCT06642948 |